Geron to Present at 2019 Cantor Global Healthcare Conference
September 26, 2019 16:18 ET
|
Geron Corporation
MENLO PARK, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a...
Onconova Therapeutics, Inc. Announces $3.4 Million Registered Direct Offering of Common Stock
September 23, 2019 08:52 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit
September 16, 2019 07:30 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
August 26, 2019 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Onconova Therapeutics, Inc. Reports Business Highlights and Second Quarter 2019 Financial Results
August 14, 2019 07:30 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Onconova Therapeutics and Mission Bio Partner to Advance Precision Oncology Clinical Trials Employing Single-Cell Genomics
August 12, 2019 07:30 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa. and SOUTH SAN FRANCISCO, Calif., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel...
Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
August 08, 2019 08:08 ET
|
Geron Corporation
MENLO PARK, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the opening of patient screening and enrollment for the Phase 3 portion of IMerge to evaluate...
Geron Corporation Reports Second Quarter 2019 Financial Results and Recent Events
August 01, 2019 16:05 ET
|
Geron Corporation
MENLO PARK, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the second quarter ended June 30, 2019, and recent events. The Company...
Geron to Announce Second Quarter Financial Results on August 1, 2019
July 25, 2019 08:00 ET
|
Geron Corporation
MENLO PARK, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2019 financial results after the market closes on...
Geron Enhances Oncology Expertise to Advance Corporate Objectives
July 18, 2019 16:15 ET
|
Geron Corporation
MENLO PARK, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointments of Sharon McBain as Vice President, Global Regulatory Affairs and Lynn Bodarky...